Home > Polymers, Specialty Chemicals & Advanced Materials > Levocarnitine Market
Levocarnitine Market size will see noticeable growth over 2023-2032 driven by the increasing prevalence of kidney diseases that lead to carnitine deficiencies in patients undergoing dialysis.
Levocarnitine or L-carnitine supplements are witnessing rising demand for the management of symptoms associated with cancer treatments such as chemotherapy-induced fatigue. Over the past decade, cancer prevalence has surged significantly, further driving the need for adequate therapies and assisting medications. Moreover, the rapidly escalating geriatric population will play a pivotal role in expanding the cancer patient pool and proliferating the need for L-carnitine medications.
As per the American Cancer Society, by 2040, the world is projected to see a rise of 27.5 million new cancer cases and deaths of 16.3 million cancer patients, primarily due to the growing aging population. Levocarnitine supplements will also gain significant demand for cardiovascular disease treatment with deteriorating lifestyles and the growing risks of heart disorders.
The consumption of levocarnitine tablets for treating mental and physical fatigue, reducing fat mass in older people, improving muscle mass, and preventing hair loss will rise notably over the forthcoming period. However, the surging concerns associated with side effects from excessive intake of carnitine supplements such as seizures, abdominal cramps, nausea, and muscle weakness may impede product demand.
Additionally, the outbreak of the Russia-Ukraine war is predicted to affect the levocarnitine market dynamics with a significant impact on manufacturing. The geopolitical conflict caused massive supply chain disruptions making it difficult for manufacturers to source raw materials and distribute products internationally. Hence, several industry players are likely to struggle with the growing supply-demand gap amidst the war.
In terms of end-use, the levocarnitine industry remuneration from weight management is expected to grow remarkably by 2032 due to the increasing prevalence of obesity in children. Childhood obesity has become a major health concern across developed and developing countries with the high predominance of fatty diets. For instance, as per the World Obesity Atlas 2023 report, childhood obesity in India is estimated to increase by 9.1% by 2035. Hence, the growing emphasis on weight management among children and young adults will spur the demand for levocarnitine supplements.
Regionally, the Middle East & Africa levocarnitine market is set to record stellar growth by 2032 driven by the growing concerns associated with nutrient deficiencies and food insecurity. Rapid westernization of lifestyles in the MEA region has led to high consumption of fast foods, like sweetened & carbonated beverages, leading to poor dietary habits and risks of lifestyle disorders. The UAE has one of the largest diabetic patient pools in the world with a prevalence rate of 18.7%, which is anticipated to reach 21.4% by 2030. This scenario is proliferating the need for supplements and medications to tackle chronic illnesses, thereby influencing the industry growth.
Leading players in the levocarnitine market include Lonza Group, Ningbo Honor Chemtech, AIDP, Biosynth AG, Alfa Aesar (Thermo Fisher Scientific), and Northeast Pharmaceutical Group, among others. These firms are focusing on the expansion of their production capacities to boost their market presence and achieve a competitive lead. For instance, in March 2023, Lonza Group completed the establishment of its cGMP clinical and commercial drug manufacturing unit in Visp, Switzerland.